Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Posted inClinical Updates Dermatology news

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients with moderate-to-severe hidradenitis suppurativa.
Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
Posted inAllergy & Immunology Dermatology news

Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa

The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therapeutic avenue for structural skin damage.
Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial
Posted inDermatology news

Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial

A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability of superiority, highlighting a promising new mechanism for neutrophil-driven dermatological inflammation.
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Posted inClinical Updates Dermatology Gastroenterology Internal Medicine news

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.